Previous 10 | Next 10 |
A team of researchers from Nottingham Trent University and the University of Sheffield is developing a first-of-its-kind finger-prick test to test for brain cancer. The research team says the simple test could make it easier to spot recurring brain tumors and even extend the lives of tens of tho...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
CNS Pharmaceuticals Inc. (CNSP) is expected to report for Q1 2024
Researchers from Stanford Medicine have found that lung cancer cells can spread to the brain and hide from the immune system by pretending to be “baby neurons.” After originating in the lungs, these cancer cells can metastasize into the brain and avoid detection by convincing neur...
2023-10-25 10:00:16 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in F...
A major marijuana company has announced that it will begin supplying cannabis to a Spanish clinical trial investigating marijuana’s potential as a glioblastoma treatment. Tilray Brands subsidiary Tilray Medical will sponsor an upcoming clinical study to test whether marijuana can treat g...
CNS Pharmaceuticals (NASDAQ: CNSP) recently announced rapid enrollment in its potentially pivotal study involving its flagship drug candidate, Berubicin, and is moving closer to reporting the results of its drive toward a new treatment for the effectively incurable brain cancer glioblastoma (...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured at this month’s Virtual Investor Ask the CEO Conference. CNS Pharmaceuticals CEO...
Live moderated webcast with John Climaco, Chief Executive Officer of CNS Pharmaceuticals on Tuesday, October 24 th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / October 19, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in th...
Current brain tumor diagnosis protocols usually involve magnetic resonance imaging (MRI) and computerized tomography (CT) scans followed by tissue biopsy or surgical resection. Although tissue biopsies are less invasive than surgical resection, both are relatively invasive procedures that involve...
News, Short Squeeze, Breakout and More Instantly...
CNS Pharmaceuticals Inc. Company Name:
CNSP Stock Symbol:
NYSE Market:
CNS Pharmaceuticals Inc. Website:
HOUSTON, TX / ACCESSWIRE / July 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its ab...
New research suggests that cancer may have been plaguing individuals even thousands of years ago. Researchers at the University of Cambridge’s Duckworth Laboratory Collection studied skulls obtained from Ancient Egypt, observing lesions which they believe may have been left by malignant t...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in tomorrow’s Virtual Investor Closing Bell Series. According to the announcemen...